New book by Larry Connors - Click here to read more
Stock Profiler.US, LLC welcomes Investors and Companies alike to join us in our pursuit of excellence. Companies who want to broadcast their message are encouraged to contact us at www.stockprofiler.us. Sign up for our Free Newsletter at www.stockprofiler.us.
-------------------------------------------
Seven Arts Pictures plc (OTCBB:SAPXF) (PLUS:SAPP) closed at $0.44 Friday, trading 69,000 shares.
Company News- June 23, 2008: Seven Arts SignificantSeven Arts Pictures Signs Anthony Hickox to Direct and Supermodel Julie Ordon to Star in Catwalk
Seven Arts Pictures plc (the Company) (OTCBB:SAPXF) (PLUS:SAPP) announced earlier today that famed director Anthony Hickox, director of Waxwork and Hellraiser III: Hell On Earth, is signed to direct the Companys new horror film Catwalk. Tony Hickox recently completed the suspense thriller Knife Edge with Seven Arts Pictures, which is scheduled for release in FY 2009.
The Company further announced that Julie Ordon has signed to star in Catwalk. Julie Ordon is well-known as the face and body in the Victoria's Secret catalog, the cover of magazines like Glamour and Elle, and she's acted in several European and American films. Ordon appeared on the cover of the French edition of Playboy in December 2007, and she is the face for Chanel Rouge Allure lipstick shot by Bettina Rheims. She recently attended the Cannes Film Festival to announce her role.
Catwalk follows the story of a stunning young woman who is taking the modeling industry by storm as she is drawn into the always exciting yet oftentimes dangerous world of high fashion, glamour and excess. The fact that the city is gripped by fear and speculation following the brutal murders of four supermodels is not enough to slow her down. Only when a whirlwind of fame starts to threaten her sense of identity, she moves closer to discovering the darker secrets of who and what she is.
We are thrilled to announce that we have signed Julie Ordon to star in Catwalk, said company Founder and Chairman Peter Hoffman. Julie has established a significant fan base from around the world throughout her modeling career and we are proud to have signed this versatile talent. The horror genre continues to be popular throughout the world and Anthony Hickox is a well known and popular director with horror fans.
For nearly a decade, Seven Arts, PLC has remained a prominent full service independent producer and distributor of quality feature films. Under the experienced hand of Founder and Chairman Peter Hoffman, the company has distinguished itself as a consistent source for both quality films that boast festival cache, as well as highly-marketable big budget feature films that appeal to a worldwide audience.
About Seven Arts:
Seven Arts Pictures plc (SAP, 7 Arts or the Company) was founded in 2002 as an independent motion picture production and distribution company engaged in the development, acquisition, financing, production, and licensing of theatrical motion pictures for exhibition in domestic (i.e. the United States and Canada) and foreign theatrical markets, and for subsequent worldwide release in other forms of media, including home video and pay and free television.
-------------------------------------------
i2Telecom International, Inc. (OTCBB: ITUI | Quote | Chart | News | PowerRating) closed at $0.135 Friday, trading 5,299,224 shares.
Company News- June 23, 2008: i2Telecom International Expects 2008 Revenues To More Than Quintuple to Over $5 Million
i2Telecom International, Inc. ("i2Telecom") (OTCBB: ITUI), a developer of award-winning patented and innovative high-quality Voice-over-Internet Protocol ("VoIP") products and services, announced earlier today that it expects revenues from the sale of VOIP products and related services to exceed $5 million in the year ending December 31, 2008, compared with less than $1 million in revenues during 2007.
This anticipated revenue growth will be driven by revenue-sharing and licensing agreements involving the Companys new MyGlobalTalk technology. In addition, the Company may have the opportunity to realize further profits from the monetization of a portion of its growing intellectual property portfolio. The Company currently has patent applications pending related to over a dozen different additional important VoIP technologies, all of which are deployed today in the Companys VoIP technology offerings.
The Company attributes much of the anticipated acceleration in revenue growth to its new patent-pending MyGlobalTalk technology, which has been met with great enthusiasm among current and prospective customers. MyGlobalTalk is an innovative, unique and proprietary software application developed internally by i2Telecoms R&D team.
MyGlobalTalk places Internet telephony in the hands of every cellular phone user, independent of wireless carrier technology, handset manufacturer, or the type of wireless carrier voice/data plan involved.
Once MyGlobalTalk is installed on a cellular handset, users are able to call any telephone in the world directly from their cellular phones using VoIP technology, at a fraction of normal long-distance rates.
MyGlobalTalk utilizes a prepaid, pay as you go plan structure and no long-term contract is required.
Additionally, MyGlobalTalk is fully functional without requiring local access to the Internet or proximity to an Internet hotspot.
MyGlobalTalk users also need not wait for the availability of dual-mode WiFi phones, because MyGlobalTalkTM provides the benefits of dual-mode phones at a fraction of the cost, using customers existing mobile handsets.
MyGlobalTalk does not require carriers to participate, since users can sign-up independently for the service.
Market response to MyGlobalTalk has been tremendous, and we anticipate adding a significant number of new customers in the near future, commented Paul Arena, Chief Executive Officer of i2Telecom International, Inc. The explosive growth in wireless service, with approximately 2.6 billion GSM users worldwide and approximately 220 million cellular users in the United States alone, has greatly expanded the opportunities to access Mobile VoIP technology.
MyGlobalTalk allows users to conveniently make low-cost long distance calls from their cell phones to anywhere in the world.
MyGlobalTalk has recently received a number of awards, including the 2007 INTERNET TELEPHONY(R) Magazine's 'Product of the Year' Award, the 'Best of Show' Award at the IT Expo East 2008, the 2007 'Product of the Year' Award by Unified Communications Magazine, and the 2007 'Product of the Year' Award by Communications Magazine. MyGlobalTalk was also the subject of this months cover story in the leading industry trade journal INTERNET TELEPHONY Magazine.
The addition of MyGlobalTalk to our family of proprietary VoIP technology solutions will allow i2Telecom to deliver a unique, low-cost telephony service to businesses and consumers by combining the benefits of unparalleled mobility with VoIP technology, continued Arena. MyGlobalTalk is the first VoIP service of its kind and provides higher-level user functionality to wireless users. The VoIP market is transitioning from an early adopter phase into a practical, dependable service offering that meets the telephony requirements of a much broader market, and we believe i2Telecom will emerge as one of the leading independent software development companies in the industry. We believe ongoing changes within the telecom industry will continue to reward innovative and nimble companies.
Our channel distribution response to MyGlobalTalk has been very enthusiastic, and negotiations on a number of revenue-sharing and licensing agreements are underway. Based upon contracts and initiatives that are already in place, we expect i2Telecoms revenues to approach $2 million in the third quarter of 2008, or more than double the Companys revenues for the entire year ended December 31, 2007. Revenues should approximate $3 million in the fourth quarter, resulting in full-year 2008 revenues in excess of $5 million, concluded Arena.
About i2Telecom International, Inc.
i2Telecom International, Inc. is a developer of award-winning patented and innovative high-quality Voice-over-Internet Protocol ("VoIP") products and services that employ best-of-breed VoIP technology and use a combination of the Company's own services network and the Internet to deliver high-quality phone calls, streaming video and text chat to customers on a global scale. i2Telecom International provides its VoiceStick, MyGlobalTalk, Digital Portal communications and microgateway adapters for VoIP long-distance and other enhanced communication services to its subscribers. Its patent pending services technology platform is compliant with the Session Initiation Protocol ("SIP") telecommunications industry standard. For additional information visit www.i2telecom.com or www.voicestick.com or www.myglobaltalk.com or call 404-567-4750.
-------------------------------------------
Oncolin Therapeutics, Inc., (OTCBB:OCOL ) closed at $0.20 Friday, trading 92,675 shares.
Company News- June 23, 2008: Oncolin Appoints Member of National Cancer Institute Advisory Board to Its Scientific Advisory Board
Oncolin Therapeutics, Inc., (OTCBB:OCOL) is very pleased to have announced earlier today that Dr. Daniel Von Hoff has joined the company s Scientific Advisory Board (SAB). Dr. Von Hoff is generally considered to be one of the worlds leading experts in oncology drug development and is an advisor in some capacity to a large number of oncology companies.
Dr. Von Hoff was appointed to President Bushs National Cancer Advisory Board in June 2004. Dr. Von Hoff is the past President of the American Association for Cancer Research (the worlds largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved for patients with leukemia). He is founder and the Editor Emeritus of Investigational New Drugs The Journal of New Anticancer Agents; and, Editor-in-Chief of Molecular Cancer Therapeutics.
Daniel D. Von Hoff, M.D., is currently Physician in Chief, Senior Investigator and Director of Translational Research at the Translational Genomics Research Institutes (TGen) Translational Drug Development Division and Head, Pancreatic Cancer Research Program in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and Chief Scientific Officer, Scottsdale Clinical Research Institute. He has done work on the development of many anticancer agents, including paclitaxel, docetaxel, gemcitabine, camptosar and hab-paclitaxel.
Oncolin Therapeutics is very excited to have someone with Dr Von Hoff s stature and experience as a member of our SAB. His oncology development experience will be a major addition to our advisory board, said Dr. Donald Picker, COO of Oncolin.
About Oncolin Therapeutics, Inc.
Headquartered in Houston, Texas, Oncolin Therapeutics, Inc. is a publicly traded biopharmaceutical company that engages in the discovery, development and commercialization of novel selective anticancer therapies. Additional information about Oncolin can be found on the web at www.oncolinthera.com.
-------------------------------------------
The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Stockprofiler.US affiliates has not been compensated for services rendered; Stockprofiler.US affiliates is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers, go to www.stockprofiler.us) (disclaimers).
CONTACT: StockProfiler.US e-mail: info@stockprofiler.us WWW: http://www.stockprofiler.us
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
